Comparative Pharmacology
Head-to-head clinical analysis: JANUVIA versus SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JANUVIA versus SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE.
JANUVIA vs SAXAGLIPTIN AND METFORMIN HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective inhibitor of dipeptidyl peptidase-4 (DPP-4), increasing levels of active incretin hormones (GLP-1, GIP), enhancing glucose-dependent insulin secretion and suppressing glucagon release.
Saxagliptin inhibits dipeptidyl peptidase-4 (DPP-4), increasing incretin levels (GLP-1, GIP), enhancing glucose-dependent insulin secretion, and suppressing glucagon release. Metformin reduces hepatic gluconeogenesis, decreases intestinal glucose absorption, and improves insulin sensitivity.
100 mg orally once daily
Initial dose: 2.5 mg saxagliptin/500 mg metformin hydrochloride orally twice daily with meals. Titrate up to max 5 mg/1000 mg twice daily.
None Documented
None Documented
Terminal elimination half-life: 12.4 hours. Clinical context: supports once-daily dosing in patients with normal renal function.
Saxagliptin: 2.5 hours; 5-hydroxy saxagliptin (active metabolite): 3.1 hours. Metformin: 4.5-6.2 hours. Total combined half-life 2-6 hours, requiring twice-daily dosing.
Renal: approximately 87% (79% unchanged sitagliptin, 16% metabolites). Fecal/biliary: 13% (metabolites and unchanged drug).
Saxagliptin: 75% renal (50% unchanged, 25% as metabolite), 22% fecal. Metformin: 90-100% renal unchanged via tubular secretion.
Category C
Category A/B
DPP-4 Inhibitor
DPP-4 Inhibitor